Metabolic stress in the myocardium: Adaptations of gene expression

Journal of Molecular and Cellular Cardiology

Volumn 55, Issue 1, 2013, Pages 130-138

  Crawford, Peter A ^a   Schaffer, Jean E ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetic cardiomyopathy; Histone deacetylation; Ischemia reperfusion; MiRNA; Nuclear receptor transcription factor; Pathological hypertrophy; Protein translation

Indexed keywords

ADENOSINE TRIPHOSPHATE; MESSENGER RNA; MICRORNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR;

ADAPTATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; GENE EXPRESSION; HEART FUNCTION; HEART HYPERTROPHY; HEART MUSCLE; HUMAN; HYPOXIA; METABOLIC STRESS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; REPERFUSION INJURY; REVIEW; TRANSCRIPTION REGULATION; VASCULAR TISSUE;

ADAPTATION, BIOLOGICAL; ANIMALS; GENE EXPRESSION REGULATION; HUMANS; MYOCARDIUM; PROTEIN BIOSYNTHESIS; RNA PROCESSING, POST-TRANSCRIPTIONAL; STRESS, PHYSIOLOGICAL; TRANSCRIPTION FACTORS;

MAMMALIA;

EID: 84872683146     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2012.06.008     Document Type: Review

References (125)

1. Bing R.J. The metabolism of the heart. Harvey Lect 1955, 50:27-70.
2. Taegtmeyer H., Hems R., Krebs H.A. Utilization of energy-providing substrates in the isolated working rat heart. Biochem J 1980, 186(3):701-711.
3. Taegtmeyer H., McNulty P., Young M.E. Adaptation and maladaptation of the heart in diabetes: part I: general concepts. Circulation 2002, 105(14):1727-1733.
4. Brookheart R.T., Michel C.I., Schaffer J.E. As a matter of fat. Cell Metab 2009, 10(1):9-12.
5. Lopaschuk G.D., Ussher J.R., Folmes C.D., Jaswal J.S., Stanley W.C. Myocardial fatty acid metabolism in health and disease. Physiol Rev 2010, 90(1):207-258.
6. Wende A.R., Abel E.D. Lipotoxicity in the heart. Biochim Biophys Acta 2010, 1801(3):311-319.
7. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979, 241(19):2035-2038.
8. From A.M., Leibson C.L., Bursi F., Redfield M.M., Weston S.A., Jacobsen S.J., et al. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med 2006, 119(7):591-599.
9. Fox C.S., Coady S., Sorlie P.D., D'Agostino R.B., Pencina M.J., Vasan R.S., et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007, 115(12):1544-1550.
10. Wilson C.R., Tran M.K., Salazar K.L., Young M.E., Taegtmeyer H. Western diet, but not high fat diet, causes derangements of fatty acid metabolism and contractile dysfunction in the heart of Wistar rats. Biochem J 2007, 406(3):457-467.
11. Burgmaier M., Sen S., Philip F., Wilson C.R., Miller C.C., Young M.E., et al. Metabolic adaptation follows contractile dysfunction in the heart of obese Zucker rats fed a high-fat "Western" diet. Obesity (Silver Spring) 2010, 18(10):1895-1901.
12. Wentz A.E., d'Avignon D.A., Weber M.L., Cotter D.G., Doherty J.M., Kerns R., et al. Adaptation of myocardial substrate metabolism to a ketogenic nutrient environment. J Biol Chem 2010, 285(32):24447-24456.
13. Kehat I., Molkentin J.D. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation 2010, 122(25):2727-2735.
14. Dorn G.W. The fuzzy logic of physiological cardiac hypertrophy. Hypertension 2007, 49(5):962-970.
15. Abel E.D., Doenst T. Mitochondrial adaptations to physiological versus pathological cardiac hypertrophy. Cardiovasc Res 2011, 90:234-242.
16. Shiojima I., Sato K., Izumiya Y., Schiekofer S., Ito M., Liao R., et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 2005, 115(8):2108-2118.
17. Schiekofer S., Shiojima I., Sato K., Galasso G., Oshima Y., Walsh K. Microarray analysis of Akt1 activation in transgenic mouse hearts reveals transcript expression profiles associated with compensatory hypertrophy and failure. Physiol Genomics 2006, 27(2):156-170.
18. DeBosch B., Treskov I., Lupu T.S., Weinheimer C., Kovacs A., Courtois M., et al. Akt1 is required for physiological cardiac growth. Circulation 2006, 113(17):2097-2104.
19. Matsui T., Nagoshi T., Hong E.-G., Luptak I., Hartil K., Li L., et al. Effects of chronic Akt activation on glucose uptake in the heart. Am J Physiol Endocrinol Metab 2006, 290(5):E789-E797.
20. Taegtmeyer H. Genetics of energetics: transcriptional responses in cardiac metabolism. Ann Biomed Eng 2000, 28:871-876.
21. Pound K.M., Sorokina N., Ballal K., Berkich D.A., Fasano M., Lanoue K.F., et al. Substrate-enzyme competition attenuates upregulated anaplerotic flux through malic enzyme in hypertrophied rat heart and restores triacylglyceride content: attenuating upregulated anaplerosis in hypertrophy. Circ Res 2009, 104(6):805-812.
22. Davila-Roman V.G., Vedala G., Herrero P., de las Fuentes L., Rogers J.G., Kelly D.P., et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2002, 40(2):271-277.
23. Neglia D., De Caterina A., Marraccini P., Natali A., Ciardetti M., Vecoli C., et al. Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2007, 293(6):H3270-H3278.
24. Heather L.C., Cole M.A., Lygate C.A., Evans R.D., Stuckey D.J., Murray A.J., et al. Fatty acid transporter levels and palmitate oxidation rate correlate with ejection fraction in the infarcted rat heart. Cardiovasc Res 2006, 72(3):430-437.
25. Ricote M., Glass C.K. PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta 2007, 1771(8):926-935.
26. Rakhshandehroo M., Sanderson L.M., Matilainen M., Stienstra R., Carlberg C., de Groot P.J., et al. Comprehensive analysis of PPARalpha-dependent regulation of hepatic lipid metabolism by expression profiling. PPAR Res 2007, 2007:26839.
27. Xu L., Glass C.K., Rosenfeld M.G. Coactivator and corepressor complexes in nuclear receptor function. Curr Opin Genet Dev 1999, 9(2):140-147.
28. Brown J.D., Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 2007, 115(4):518-533.
29. Finck B.N., Lehman J.J., Leone T.C., Welch M.J., Bennett M.J., Kovacs A., et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 2002, 109(1):121-130.
30. Finck B.N., Han X., Courtois M., Aimond F., Nerbonne J.M., Kovacs A., et al. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A 2003, 100(3):1226-1231.
31. Fischer Y., Thomas J., Sevilla L., Munoz P., Becker C., Holman G., et al. Insulin-induced recruitment of glucose transporter 4 (GLUT4) and GLUT1 in isolated rat cardiac myocytes. Evidence of the existence of different intracellular GLUT4 vesicle populations. J Biol Chem 1997, 272(11):7085-7092.
32. Russell R.R.I.I.I., Yin R., Caplan M.J., Hu X., Ren J., Shulman G.I., et al. Additive effects of hyperinsulinemia and ischemia on myocardial GLUT1 and GLUT4 translocation in vivo. Circulation 1998, 98(20):2180-2186.
33. Becker C., Sevilla L., Tomas E., Palacin M., Zorzano A., Fischer Y. The endosomal compartment is an insulin-sensitive recruitment site for GLUT4 and GLUT1 glucose transporters in cardiac myocytes. Endocrinology 2001, 142(12):5267-5276.
34. Montgomery R.L., Potthoff M.J., Haberland M., Qi X., Matsuzaki S., Humphries K.M., et al. Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J Clin Invest 2008, 118(11):3588-3597.
35. Cook W.S., Yeldandi A.V., Rao M.S., Hashimoto T., Reddy J.K. Less extrahepatic induction of fatty acid beta-oxidation enzymes by PPAR alpha. Biochem Biophys Res Commun 2000, 278(1):250-257.
36. Haemmerle G., Lass A., Zimmermann R., Gorkiewicz G., Meyer C., Rozman J., et al. Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science 2006, 312(5774):734-737.
37. Haemmerle G., Moustafa T., Woelkart G., Buttner S., Schmidt A., van de Weijer T., et al. ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-alpha and PGC-1. Nat Med 2011, 17(9):1076-1085.
38. Leone T.C., Lehman J.J., Finck B.N., Schaeffer P.J., Wende A.R., Boudina S., et al. PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol 2005, 3(4):e101.
39. Arany Z., He H., Lin J., Hoyer K., Handschin C., Toka O., et al. Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab 2005, 1(4):259-271.
40. Vianna C.R., Huntgeburth M., Coppari R., Choi C.S., Lin J., Krauss S., et al. Hypomorphic mutation of PGC-1beta causes mitochondrial dysfunction and liver insulin resistance. Cell Metab 2006, 4(6):453-464.
41. Leone T.C., Weinheimer C.J., Kelly D.P. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci U S A 1999, 96(13):7473-7478.
42. Kienesberger P.C., Pulinilkunnil T., Young M.E., Kershaw E.E., Dyck J.R. Abstract 14197: cardiac steatosis induced by cardiomyocyte-specific adipose triglyceride lipase deficiency is associated with impaired oxidative substrate metabolism and hypertrophy. Circulation 2011, 124:A14197.
43. Son N.H., Park T.S., Yamashita H., Yokoyama M., Huggins L.A., Okajima K., et al. Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J Clin Invest 2007, 117(10):2791-2801.
44. Morrow J.P., Katchman A., Son N.H., Trent C.M., Khan R., Shiomi T., et al. Mice with cardiac overexpression of peroxisome proliferator-activated receptor gamma have impaired repolarization and spontaneous fatal ventricular arrhythmias. Circulation 2012, 124(25):2812-2821.
45. Son N.H., Yu S., Tuinei J., Arai K., Hamai H., Homma S., et al. PPARgamma-induced cardiolipotoxicity in mice is ameliorated by PPARalpha deficiency despite increases in fatty acid oxidation. J Clin Invest 2010, 120:3443-3454.
46. Nesto R.W., Bell D., Bonow R.O., Fonseca V., Grundy S.M., Horton E.S., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 2003, 108(23):2941-2948.
47. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366(9493):1279-1289.
48. Birnbaum Y., Long B., Qian J., Perez-Polo J.R., Ye Y. Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR-gamma-independent manner. Basic Res Cardiol 2011, 106(3):431-446.
49. Choi J.H., Banks A.S., Kamenecka T.M., Busby S.A., Chalmers M.J., Kumar N., et al. Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation. Nature 2011, 477(7365):477-481.
50. Krishnan J., Suter M., Windak R., Krebs T., Felley A., Montessuit C., et al. Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy. Cell Metab 2009, 9(6):512-524.
51. Duan S.Z., Ivashchenko C.Y., Russell M.W., Milstone D.S., Mortensen R.M. Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice. Circ Res 2005, 97(4):372-379.
52. Gordon J.W., Shaw J.A., Kirshenbaum L.A. Multiple facets of NF-kappaB in the heart: to be or not to NF-kappaB. Circ Res 2011, 108(9):1122-1132.
53. Liu Q., Chen Y., Auger-Messier M., Molkentin J.D. Interaction between NFkappaB and NFAT coordinates cardiac hypertrophy and pathological remodeling. Circ Res 2012, 110(8):1077-1086.
54. Burkart E.M., Sambandam N., Han X., Gross R.W., Courtois M., Gierasch C.M., et al. Nuclear receptors PPARbeta/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart. J Clin Invest 2007, 117(12):3930-3939.
55. Cheng L., Ding G., Qin Q., Huang Y., Lewis W., He N., et al. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 2004, 10(11):1245-1250.
56. Panagia M., Gibbons G.F., Radda G.K., Clarke K. PPAR-alpha activation required for decreased glucose uptake and increased susceptibility to injury during ischemia. Am J Physiol Heart Circ Physiol 2005, 288(6):H2677-H2683.
57. Yue T.L., Nerurkar S.S., Bao W., Jucker B.M., Sarov-Blat L., Steplewski K., et al. In vivo activation of peroxisome proliferator-activated receptor-delta protects the heart from ischemia/reperfusion injury in Zucker fatty rats. J Pharmacol Exp Ther 2008, 325(2):466-474.
58. Bulhak A.A., Jung C., Ostenson C.G., Lundberg J.O., Sjoquist P.O., Pernow J. PPAR-alpha activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: involvement of the PI3-Kinase/Akt and NO pathway. Am J Physiol Heart Circ Physiol 2009, 296(3):H719-H727.
59. Morrison A., Li J. PPAR-gamma and AMPK-advantageous targets for myocardial ischemia/reperfusion therapy. Biochem Pharmacol 2011, 82(3):195-200.
60. Alaynick W.A., Kondo R.P., Xie W., He W., Dufour C.R., Downes M., et al. ERRgamma directs and maintains the transition to oxidative metabolism in the postnatal heart. Cell Metab 2007, 6(1):13-24.
61. Giguere V. Transcriptional control of energy homeostasis by the estrogen-related receptors. Endocr Rev 2008, 29(6):677-696.
62. Huss J.M., Imahashi K., Dufour C.R., Weinheimer C.J., Courtois M., Kovacs A., et al. The nuclear receptor ERRalpha is required for the bioenergetic and functional adaptation to cardiac pressure overload. Cell Metab 2007, 6(1):25-37.
63. Arany Z., Novikov M., Chin S., Ma Y., Rosenzweig A., Spiegelman B.M. Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-gamma coactivator 1alpha. Proc Natl Acad Sci U S A 2006, 103(26):10086-10091.
64. Riehle C., Wende A.R., Zaha V.G., Pires K.M., Wayment B., Olsen C., et al. PGC-1beta deficiency accelerates the transition to heart failure in pressure overload hypertrophy. Circ Res 2011, 109(7):783-793.
65. McDermott-Roe C., Ye J., Ahmed R., Sun X.M., Serafin A., Ware J., et al. Endonuclease G is a novel determinant of cardiac hypertrophy and mitochondrial function. Nature 2011, 478(7367):114-118.
66. Hansson A., Hance N., Dufour E., Rantanen A., Hultenby K., Clayton D.A., et al. A switch in metabolism precedes increased mitochondrial biogenesis in respiratory chain-deficient mouse hearts. Proc Natl Acad Sci U S A 2004, 101(9):3136-3141.
67. Bugger H., Abel E.D. Endonuclease g: the link between mitochondria and cardiac hypertrophy?. Circ Res 2012, 110(3):378-380.
68. Oka S., Alcendor R., Zhai P., Park J.Y., Shao D., Cho J., et al. PPARalpha-Sirt1 complex mediates cardiac hypertrophy and failure through suppression of the ERR transcriptional pathway. Cell Metab 2011, 14(5):598-611.
69. Smeets P.J., Teunissen B.E., Willemsen P.H., van Nieuwenhoven F.A., Brouns A.E., Janssen B.J., et al. Cardiac hypertrophy is enhanced in PPAR alpha-/- mice in response to chronic pressure overload. Cardiovasc Res 2008, 78(1):79-89.
70. Smeets P.J., de Vogel-van den Bosch H.M., Willemsen P.H., Stassen A.P., Ayoubi T., van der Vusse G.J., et al. Transcriptomic analysis of PPARalpha-dependent alterations during cardiac hypertrophy. Physiol Genomics 2008, 36(1):15-23.
71. Jamshidi Y., Montgomery H.E., Hense H.W., Myerson S.G., Torra I.P., Staels B., et al. Peroxisome proliferator-activated receptor alpha gene regulates left ventricular growth in response to exercise and hypertension. Circulation 2002, 105(8):950-955.
72. Cresci S., Huss J.M., Beitelshees A.L., Jones P.G., Minton M.R., Dorn G.W., et al. A PPARalpha promoter variant impairs ERR-dependent transactivation and decreases mortality after acute coronary ischemia in patients with diabetes. PLoS One 2010, 5(9):e12584.
73. Czubryt M.P., McAnally J., Fishman G.I., Olson E.N. Regulation of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1 alpha) and mitochondrial function by MEF2 and HDAC5. Proc Natl Acad Sci U S A 2003, 100(4):1711-1716.
74. Czubryt M.P., Olson E.N. Balancing contractility and energy production: the role of myocyte enhancer factor 2 (MEF2) in cardiac hypertrophy. Recent Prog Horm Res 2004, 59:105-124.
75. Moore M.L., Wang G.L., Belaguli N.S., Schwartz R.J., McMillin J.B. GATA-4 and serum response factor regulate transcription of the muscle-specific carnitine palmitoyltransferase I beta in rat heart. J Biol Chem 2001, 276(2):1026-1033.
76. Oh S.Y., Lee M.Y., Kim J.M., Yoon S., Shin S., Park Y.N., et al. Alternative usages of multiple promoters of the acetyl-CoA carboxylase beta gene are related to differential transcriptional regulation in human and rodent tissues. J Biol Chem 2005, 280(7):5909-5916.
77. Liang Q., De Windt L.J., Witt S.A., Kimball T.R., Markham B.E., Molkentin J.D. The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo. J Biol Chem 2001, 276(32):30245-30253.
78. Aries A., Paradis P., Lefebvre C., Schwartz R.J., Nemer M. Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proc Natl Acad Sci U S A 2004, 101(18):6975-6980.
79. Bisping E., Ikeda S., Kong S.W., Tarnavski O., Bodyak N., McMullen J.R., et al. Gata4 is required for maintenance of postnatal cardiac function and protection from pressure overload-induced heart failure. Proc Natl Acad Sci U S A 2006, 103(39):14471-14476.
80. van Berlo J.H., Elrod J.W., van den Hoogenhof M.M., York A.J., Aronow B.J., Duncan S.A., et al. The transcription factor GATA-6 regulates pathological cardiac hypertrophy. Circ Res 2010, 107(8):1032-1040.
81. Hang C.T., Yang J., Han P., Cheng H.L., Shang C., Ashley E., et al. Chromatin regulation by Brg1 underlies heart muscle development and disease. Nature 2010, 466(7302):62-67.
82. Edelstein L.C., Lagos L., Simmons M., Tirumalai H., Gelinas C. NF-kappa B-dependent assembly of an enhanceosome-like complex on the promoter region of apoptosis inhibitor Bfl-1/A1. Mol Cell Biol 2003, 23(8):2749-2761.
83. Bostrom P., Mann N., Wu J., Quintero P.A., Plovie E.R., Panakova D., et al. C/EBPbeta controls exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell 2010, 143(7):1072-1083.
84. Zhang C.L., McKinsey T.A., Chang S., Antos C.L., Hill J.A., Olson E.N. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002, 110(4):479-488.
85. Backs J., Olson E.N. Control of cardiac growth by histone acetylation/deacetylation. Circ Res 2006, 98(1):15-24.
86. Trivedi C.M., Luo Y., Yin Z., Zhang M., Zhu W., Wang T., et al. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med 2007, 13(3):324-331.
87. Kee H.J., Kook H. Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy. J Biomed Biotechnol 2011, 2011:928326.
88. Trivedi C.M., Lu M.M., Wang Q., Epstein J.A. Transgenic overexpression of Hdac3 in the heart produces increased postnatal cardiac myocyte proliferation but does not induce hypertrophy. J Biol Chem 2008, 283(39):26484-26489.
89. Battiprolu P.K., Hojayev B., Jiang N., Wang Z.V., Luo X., Iglewski M., et al. Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice. J Clin Invest 2012, 122(3):1109-1118.
90. Yan J., Young M.E., Cui L., Lopaschuk G.D., Liao R., Tian R. Increased glucose uptake and oxidation in mouse hearts prevent high fatty acid oxidation but cause cardiac dysfunction in diet-induced obesity. Circulation 2009, 119(21):2818-2828.
91. Sengupta A., Molkentin J.D., Paik J.H., DePinho R.A., Yutzey K.E. FoxO transcription factors promote cardiomyocyte survival upon induction of oxidative stress. J Biol Chem 2011, 286(9):7468-7478.
92. Kuma A., Hatano M., Matsui M., Yamamoto A., Nakaya H., Yoshimori T., et al. The role of autophagy during the early neonatal starvation period. Nature 2004, 432(7020):1032-1036.
93. Nishida K., Kyoi S., Yamaguchi O., Sadoshima J., Otsu K. The role of autophagy in the heart. Cell Death Differ 2009, 16(1):31-38.
94. Hariharan N., Maejima Y., Nakae J., Paik J., Depinho R.A., Sadoshima J. Deacetylation of FoxO by Sirt1 plays an essential role in mediating starvation-induced autophagy in cardiac myocytes. Circ Res 2010, 107:1470-1482.
95. Semenza G.L. Hypoxia-inducible factor 1: regulator of mitochondrial metabolism and mediator of ischemic preconditioning. Biochim Biophys Acta 2011, 1813(7):1263-1268.
96. Holscher M., Silter M., Krull S., von Ahlen M., Hesse A., Schwartz P., et al. Cardiomyocyte-specific prolyl-4-hydroxylase domain 2 knock out protects from acute myocardial ischemic injury. J Biol Chem 2011, 286(13):11185-11194.
97. Lu H., Buchan R.J., Cook S.A. MicroRNA-223 regulates Glut4 expression and cardiomyocyte glucose metabolism. Cardiovasc Res 2010, 86(3):410-420.
98. Caporali A., Meloni M., Vollenkle C., Bonci D., Sala-Newby G.B., Addis R., et al. Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation 2011, 123(3):282-291.
99. Villeneuve L.M., Kato M., Reddy M.A., Wang M., Lanting L., Natarajan R. Enhanced levels of microRNA-125b in vascular smooth muscle cells of diabetic db/db mice lead to increased inflammatory gene expression by targeting the histone methyltransferase Suv39h1. Diabetes 2010, 59(11):2904-2915.
100. Wang X.H., Qian R.Z., Zhang W., Chen S.F., Jin H.M., Hu R.M. MicroRNA-320 expression in myocardial microvascular endothelial cells and its relationship with insulin-like growth factor-1 in type 2 diabetic rats. Clin Exp Pharmacol Physiol 2009, 36(2):181-188.
101. Zhu H., Yang Y., Wang Y., Li J., Schiller P.W., Peng T. MicroRNA-195 promotes palmitate-induced apoptosis in cardiomyocytes by down-regulating Sirt1. Cardiovasc Res 2011, 92(1):75-84.
102. Li Y., Song Y.H., Li F., Yang T., Lu Y.W., Geng Y.J. MicroRNA-221 regulates high glucose-induced endothelial dysfunction. Biochem Biophys Res Commun 2009, 381(1):81-83.
103. Togliatto G., Trombetta A., Dentelli P., Rosso A., Brizzi M.F. MIR221/MIR222-driven post-transcriptional regulation of P27KIP1 and P57KIP2 is crucial for high-glucose- and AGE-mediated vascular cell damage. Diabetologia 2011, 54(7):1930-1940.
104. Li Y., Xu X., Liang Y., Liu S., Xiao H., Li F., et al. miR-375 enhances palmitate-induced lipoapoptosis in insulin-secreting NIT-1 cells by repressing myotrophin (V1) protein expression. Int J Clin Exp Pathol 2010, 3(3):254-264.
105. Fred R.G., Bang-Berthelsen C.H., Mandrup-Poulsen T., Grunnet L.G., Welsh N. High glucose suppresses human islet insulin biosynthesis by inducing miR-133a leading to decreased polypyrimidine tract binding protein-expression. PLoS One 2010, 5(5):e10843.
106. Matkovich S.J., Wang W., Tu Y., Eschenbacher W.H., Dorn L.E., Condorelli G., et al. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res 2010, 106(1):166-175.
107. Yang Y., Ago T., Zhai P., Abdellatif M., Sadoshima J. Thioredoxin 1 negatively regulates angiotensin II-induced cardiac hypertrophy through upregulation of miR-98/let-7. Circ Res 2011, 108(3):305-313.
108. Zhu H., Shyh-Chang N., Segre A.V., Shinoda G., Shah S.P., Einhorn W.S., et al. The Lin28/let-7 axis regulates glucose metabolism. Cell 2011, 147(1):81-94.
109. Ren X.P., Wu J., Wang X., Sartor M.A., Qian J., Jones K., et al. MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. Circulation 2009, 119(17):2357-2366.
110. Fichtlscherer S., De Rosa S., Fox H., Schwietz T., Fischer A., Liebetrau C., et al. Circulating microRNAs in patients with coronary artery disease. Circ Res 2010, 107(5):677-684.
111. Ji R., Cheng Y., Yue J., Yang J., Liu X., Chen H., et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res 2007, 100(11):1579-1588.
112. Fasanaro P., D'Alessandra Y., Di Stefano V., Melchionna R., Romani S., Pompilio G., et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem 2008, 283(23):15878-15883.
113. Chan Y.C., Khanna S., Roy S., Sen C.K. miR-200b targets Ets-1 and is down-regulated by hypoxia to induce angiogenic response of endothelial cells. J Biol Chem 2011, 286(3):2047-2056.
114. Pan Q., Shai O., Lee L.J., Frey B.J., Blencowe B.J. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 2008, 40(12):1413-1415.
115. Zhang Y., Huypens P., Adamson A.W., Chang J.S., Henagan T.M., Boudreau A., et al. Alternative mRNA splicing produces a novel biologically active short isoform of PGC-1alpha. J Biol Chem 2009, 284(47):32813-32826.
116. Yu G.S., Lu Y.C., Gulick T. Expression of novel isoforms of carnitine palmitoyltransferase I (CPT-1) generated by alternative splicing of the CPT-ibeta gene. Biochem J 1998, 334(Pt 1):225-231.
117. Kalea A.Z., Reiniger N., Yang H., Arriero M., Schmidt A.M., Hudson B.I. Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene. FASEB J 2009, 23(6):1766-1774.
118. Sengupta S., Peterson T.R., Sabatini D.M. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 2010, 40(2):310-322.
119. Crozier S.J., Bolster D.R., Reiter A.K., Kimball S.R., Jefferson L.S. Beta-oxidation of free fatty acids is required to maintain translational control of protein synthesis in heart. Am J Physiol Endocrinol Metab 2002, 283(6):E1144-E1150.
120. Crozier S.J., Anthony J.C., Schworer C.M., Reiter A.K., Anthony T.G., Kimball S.R., et al. Tissue-specific regulation of protein synthesis by insulin and free fatty acids. Am J Physiol Endocrinol Metab 2003, 285(4):E754-E762.
121. Shende P., Plaisance I., Morandi C., Pellieux C., Berthonneche C., Zorzato F., et al. Cardiac raptor ablation impairs adaptive hypertrophy, alters metabolic gene expression, and causes heart failure in mice. Circulation 2011, 123(10):1073-1082.
122. Barth A.S., Kumordzie A., Frangakis C., Margulies K.B., Cappola T.P., Tomaselli G.F. Reciprocal transcriptional regulation of metabolic and signaling pathways correlates with disease severity in heart failure. Circ Cardiovasc Genet 2011, 4(5):475-483.
123. Care A., Catalucci D., Felicetti F., Bonci D., Addario A., Gallo P., et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007, 13(5):613-618.
124. Matkovich S.J., Van Booven D.J., Youker K.A., Torre-Amione G., Diwan A., Eschenbacher W.H., et al. Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation 2009, 119(9):1263-1271.
125. Schlesinger J., Schueler M., Grunert M., Fischer J.J., Zhang Q., Krueger T., et al. The cardiac transcription network modulated by Gata4, Mef2a, Nkx2.5, Srf, histone modifications, and microRNAs. PLoS Genet 2011, 7(2):e1001313.